Hepatitis Therapeutics Market To Reach $23.62 Billion By 2033

Hepatitis Therapeutics Market Growth & Trends

The global hepatitis therapeutics market size is estimated to reach USD 23.62 billion by 2033, registering a CAGR of 3.9% from 2025 to 2033, according to a new report by Grand View Research, Inc. Few factors that are expected to drive the market over the forecast period include the rising number of hepatitis infected population, growing consumption of alcohol & drugs, and improving accessibility to hepatitis drugs.

Based on the duration for which the patient suffers, viral hepatitis is generally categorized into two types. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis. People with HIV infection & HCV-infected sexual partners, recipients of infected blood, patients who inject drugs & use intranasal drugs, and population groups who live in unhygienic conditions are at high risk of hepatitis.

Based on the estimates of WHO, approximately 400 million people are infected with at least one form of hepatitis globally, and annually nearly 1.4 people die due to the condition. In order to prevent hepatitis, few government and private agencies are actively involved in the vaccination drive to prevent hepatitis. As compared to hepatitis A and B, HCV leads to more serious complications. According to the estimates of WHO, globally annually 150 million are impacted by hepatitis C infection. Moreover, the majority of HCV infected patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

 Request a free sample copy or view report summary: Hepatitis Therapeutics Market Report

Hepatitis Therapeutics Market Report Highlights

• Based on disease, the hepatitis C segment dominated the market with the largest revenue share of 83.56% in 2024, driven by the widespread adoption of direct-acting antivirals (DAAs) that deliver high cure rates and shorter treatment durations of 8-12 weeks.

• Based on distribution channel, the hospital pharmacies segment held the largest revenue share of 53.15% in 2024, driven by the predominance of specialist-led prescribing and complex treatment protocols.

• In 2024, the North American region accounted for the majority of the revenue share, owing to high patient awareness levels and the presence of advanced healthcare infrastructure.

Hepatitis Therapeutics Market Segmentation

Grand View Research has segmented the global hepatitis therapeutics market based on disease, distribution channel, and region:

Hepatitis Therapeutics Disease Outlook (Revenue, USD Million, 2021 - 2033)

• Hepatitis A

• Hepatitis B

• Hepatitis C

• Others

Hepatitis Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

• Hospital Pharmacies

• Drug Stores and Retail Pharmacies

• Others

Hepatitis Therapeutics Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Hepatitis Therapeutics Market 

• Teva Pharmaceutical Industries Ltd.

• Bristol-Myers Squibb Company

• F. Hoffmann-La Roche Ltd

• Zydus Group

• GSK plc.

• AbbVie Inc.

• Gilead Sciences, Inc.

• Merck & Co., Inc.

• Lupin

• Cipla